Mostafa Kamandi

Mostafa Kamandi

Auto-generated profile, based on publicly available information

Mostafa Kamandi

Department of Internal Medicine, Faculty of Medicine Mashhad University of Medical Sciences Mashhad Iran

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2019 in Epidemiology and Health
Verified
Journal Article
Open access
PDF file
HDHamideh Feiz Disfani
Hamideh Feiz Disfani
MKMostafa Kamandi
Mostafa Kamandi
SMSeyed Mohammad Mousavi
Seyed Mohammad Mousavi
SSSayyed Majid Sadrzadeh
Sayyed Majid Sadrzadeh
RFRoohie Farzaneh
Roohie Farzaneh
KRKazem Rahmani
Kazem Rahmani
OBJECTIVES: Since poisoning is one of the most important preventable factors contributing to the hospitalization and death of children who present to emergency departments, this study was carried out to investigate the risk factors contributing to the incidence and mortality of acute childhood poisoning.METHODS: This hospital-based case-control study included 243 cases and 489 controls, drawn from daily admissions to the emergency departments of the included hospitals according to the inclusion and exclusion criteria.RESULTS: Gastrointestinal poisoning was the most common poisoning type, found in 87.7% of subjects, and medications were the most common cause of poisoning (49.8%). Multiple logistic regression analysis showed that a history of poisoning (odds ratio [OR], 10.44; 95% confidence interval [CI], 5.58 to 19.51; p<0.001) and the availability of poisonous substances (OR, 8.88; 95% CI, 5.41 to 14.56; p<0.001) were among the most important predictors of childhood poisoning. Respiratory poisoning (OR, 6.72; 95% CI, 1.40 to 32.07; p<0.05) and the presence of addiction in the family (OR, 4.54; 95% CI, 1.10 to 18.68; p<0.05) were the most important predictors of mortality among children with poisoning.CONCLUSIONS: Addiction and the presence of physical or psychological disorders in family members, a history of poisoning, and the availability of poisonous substances were significantly associated with the incidence of childhood poisoning and resultant mortality.

1 August 2023 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
NKNeda Kamandi
Neda Kamandi
ASAmirmohammad Soleimanian
Amirmohammad Soleimanian
AAAbolghasem Allahyari
Abolghasem Allahyari
MKMostafa Kamandi
Mostafa Kamandi
Introduction: Several A number of prognostic blood markers related tofor Diffuse Large B-Cell Lymphoma (DLBCL) have been identified, most of which are costly and not easily availableaccessible. Although the relationship between the prognostic role of RDW and some cancers has been well established, the role it of RDW plays in DLBCL patients is unclear still questionable and requires more investigations. Methods: All patients diagnosed with DLBCL who had referred to Imam Reza Hospital, during were included in this retrospective cohort study. Based onRegarding their RDW, the subjects were divided into two groups of normal (RDW ≤14.6%) and elevated RDW (RDW > 14.6%) RDW, and the outcomes were investigated. Results: One hundred fifty patients with DLBCL were included in this study. The results showed a significant relationship between the RDW values of the DLBCL patients and stage frequency distribution, relapse, mortality, and complete remission (P value 14.6% was associated with the risk of relapse (OR=2.50, P value<0.05), mortality (OR=3.59, P value<0.01), and lack of complete remission (OR=0.115, P value< 0.01). The results of the survival analysis indicated that the subjects with higher RDWs had a lower median survival rate than those with low RDWs. In addition, the mortality risk for the individuals with RDW > 14.6% was 2.44 times that of those with RDW≤14.6% (HR=2.44, P value<0.05). Conclusion: The results of this study well indicated that as an independent prognostic factor, RDW was associated with the stage of DLBCL patients, failure to achieve complete remission, disease relapse, and patient mortality. However, further studies are would be needed to realize determine the role of RDW in DLBCL patients.

3 November 2021 in medRxiv
Verified
Preprint
Open access
PDF file
KRKazem Rahmani
Kazem Rahmani
RSRasoul Shavaleh
Rasoul Shavaleh
MFMahtab Forouhi
Mahtab Forouhi
HDHamideh Feiz Disfani
Hamideh Feiz Disfani
MKMostafa Kamandi
Mostafa Kamandi
MSMoslem Soltani
Moslem Soltani
Introduction & Objective: Vaccination is one of the most important and effective ways of preventing infectious diseases, and has recently been used in the COVID-19 epidemic and pandemic. The present meta-analysis study aimed to evaluate the effectiveness of COVID-19 vaccines in reducing the incidence of infection, hospitalization, and mortality in observational studies. Materials and Methods: A systematic search was performed independently in Scopus, PubMed, ProQuest, and Google Scholar electronic databases as well as Preprint servers using the keywords under study. The heterogeneity of the studies was assessed using I 2 and χ 2 statistics, according to which the I 2 of > 50% and P -value <0.1 was reported as heterogeneity of the studies. In addition, the Pooled Vaccine Effectiveness (PVE) obtained from the studies was calculated by converting (1-Pooled estimate × 100%) based on the type of outcome. Results: A total of 54 records were included in this meta-analysis. The rate of PVE against SARS-COV 2 infection was about 71% (OR = 0.29, 95% CI: 0.23-0.36) in the first dose and 87% (OR = 0.13, 95% CI: 0.08-0.21) in the second, and the highest effectiveness in the first and second doses was that of BNT162b2 mRNA and combined studies. The PVE versus COVID-19-associated hospitalization was 73% (OR = 0.27, 95% CI: 0.18-0.41) in the first dose and 89% (OR = 0.11, 95% CI: 0.07-0.17) in the second. mRNA-1273 and combined studies in the first dose and ChAdOx1 and mRNA-1273 in the second dose had the highest effectiveness. Regarding the COVID-19-related mortality, PVE was about 28% (HR = 0.39, 95% CI: 0.23-0.45) in the first dose and 89% (HR = 0.11, 95% CI: 0.03-0.43) in the second. Conclusion: The evidence obtained from this study showed that the effectiveness of BNT162b2 mRNA, mRNA-1273, and ChAdOx1 in the first and second doses, and even combined studies were associated with increased effectiveness against SARS-COV2 infection, hospitalization, and death from COVID-19. In addition, considering that the second dose was significantly more efficient than the first one, a booster dose injection could be effective in high-risk individuals. On the other hand, it was important to observe other prevention considerations in the first days after taking the first dose.

18 October 2020 in Immunopathologia Persa
Verified
Journal Article
Open access
PDF file
MSMohsen Seddigh-Shamsi
Mohsen Seddigh-Shamsi
SMShima Nabavi Mahali
Shima Nabavi Mahali
MMMahnaz Mozdourian
Mahnaz Mozdourian
AAAbolghasem Allahyari
Abolghasem Allahyari
NSNeda Saeedian
Neda Saeedian
ZBZahra Rezaei Borojerdi
Zahra Rezaei Borojerdi
Introduction:Human coronavirus disease 2019 (COVID-19) is an emerging respiratory disease that has become pandemic worldwide. The patients have a range of mild to severe symptoms, such as pneumonia, acute respiratory distress syndrome, arrhythmia, shock, and other organs involvement. Clinical and hematological evidence can serve as a prognostic factor to detect severe cases of COVID-19. Objectives: The present study aimed to evaluate hematological parameters related to the severity of the disease in COVID-19 patients in Mashhad, Eastern Iran. Patients and Methods: All the individuals with positive real-time reverse transcription-polymerase chain reaction test results and the patients with clinical symptoms whose computed tomography scan results were matched with the diagnosis of viral pneumonia were included in the study. The hematological examinations and complete blood count of the patients were performed by the healthcare personnel through collecting blood samples at the time of admission and discharge from the hospital. Results: In total, 189 COVID-19 patients were included in the study, 47.6% and 58.73% of whom were over 60 years old and male, respectively. Investigation of the hematological parameters revealed that the number of white blood cells, mean value of corpuscular volume, number of platelets, and lymph count had significantly increased at the time of discharge (P<0.01). On the other hand, red blood cells, hemoglobin, hematocrit, mean corpuscular hemoglobin, mean corpuscular hemoglobin, and red cell distribution width values were significantly higher at the time of admission in comparison to discharge (P<0.01). Furthermore, it was found that male gender had a significant relationship with the development of lymphopenia in the patients (P=0.021). Conclusion: It can be concluded that hematological parameters and inflammatory biomarkers in COVID-19 patients could potentially act as the independent factors and affect the prognosis of the disease.

Verified
Journal Article
Open access
HDHamideh Feiz Disfani
Hamideh Feiz Disfani
MKMostafa Kamandi
Mostafa Kamandi
SHSeyyedeh Bahareh Hoseini
Seyyedeh Bahareh Hoseini
NSNarges Shirazi
Narges Shirazi
MPMaryam Panahi
Maryam Panahi
Mild head trauma often causes several complications and disabilities including nausea and vomiting in hospitalized people. The aim of the present study was to compare the effectiveness of metoclopramide and ondansetron, and compare it with placebo to control nausea in the patients with mild head trauma admitted to the emergency department. This is a randomized double-blind placebo-controlled clinical trial conducted on the patients with mild head trauma and normal brain CT scans who were admitted to the emergency department within 24 hours after the injury. The subjects were randomly divided into three groups of ondansetron (n= 41), metoclopramide (n= 44), and placebo (n= 39), and the severity of nausea and vomiting was assessed using the visual analogue scale (VAS). A total of 124 patients with mild head trauma were included in the study. The assessment of the VAS scores during the study showed that over time, the patients in all three groups had reduced nausea (p<0.01). On the other hand, the percentage change of the VAS score indicated that metoclopramide and ondansetron had the greatest changes (46.97% and 66.90%, respectively) within 15 and 30 minutes after the injection, respectively. The results of the present study showed that ondansetron and metoclopramide had similar effects on nausea in the patients with mild head trauma. However, metoclopramide was most effective in 15 minutes and ondansetron in 30 minutes after the injection.

26 June 2020 in Trials
Verified
Journal Article
Open access
PDF file
AAAbolghasem Allahyari
Abolghasem Allahyari
HRHossein Rahimi
Hossein Rahimi
MKMajid Khadem-Rezaiyan
Majid Khadem-Rezaiyan
ZMZahra Mozaheb
Zahra Mozaheb
MSMohsen Seddigh-Shamsi
Mohsen Seddigh-Shamsi
MNMohammad Moeini Nodeh
Mohammad Moeini Nodeh
Objectives: In this study, we investigate the effect of hydroxychloroquine on the prevention of Novel Coronavirus Disease (COVID-19) in cancer patients being treated. Trial design: This is a multi-centre, two-arm, parallel-group, triple-blind, phase 2-3 randomised controlled trial. Participants: All patients over the age of 15 from 5 types of cancer are included in the study. Patients with acute lymphoid and myeloid leukemias in the first line treated with curative intent, patients with high-grade non-Hodgkin's lymphoma treated with leukemia protocols and patients with non-metastatic breast and colon cancer in the first line of treatment will enter the study. The exclusion criteria will include known sensitivity to Hydroxychloroquine, weight below 35 kilograms, history of retinopathy, history of any cardiac disease, acute respiratory tract infection in the last 2 months, having COVID-19 in the first two weeks of entering the trial, having Diabetes Mellitus, having an immuno-suppressive disease other than cancer, having chronic pulmonary disease and taking immuno-suppressant drug other than chemotherapeutic agents for current cancer. This study is performed in five academic centres affiliated to Mashhad University of Medical Sciences, Mashhad, Iran. Intervention and comparator: Patients are randomly assigned to two groups; one being given hydroxychloroquine and the other is given placebo. During two months of treatment, the two groups are treated with either hydroxychloroquine (Amin® Pharmaceutical Company, Isfahan, Iran) or placebo (identical in terms of shape, colour, smell) as a single 200 mg tablet every other day. Patients will be monitored for COVID-19 symptoms during the follow-up period. If signs or symptoms occur (fever, cough, shortness of breath), they will be examined and investigated with a high-resolution computed tomography (CT) scan of the lungs, COVID-19 specific IgM, IgG antibody assay and a nucleic acid amplification test (NAT) for the SARS-CoV-2 virus. Main outcomes: The primary end point of this study is to investigate the incidence of COVID-19 in patients being treated for their cancer over a 2-month period. Randomisation: Randomisation will be performed using randomly permuted blocks. By using an online website (www.randomization.com) the randomization sequence will be produced by quadruple blocks. The allocation ratio in intervention and control groups is 1:1. Blinding (masking): Participants and caregivers do not know whether the patient is in the intervention or the control group. The outcome assessor and the data analyst are also blinded to group assignment. Numbers to be randomised (sample size): The calculated total sample size is 60 patients, with 30 patients in each group. Trial Status: The trial began on April 14, 2020 and recruitment is ongoing. Recruitment is anticipated to be completed by June 14, 2020 There has been no change in study protocol since approval, protocol version 1 was approved April 12, 2020. Trial registration: This trial has been registered by the title of “Effect of Hydroxychloroquine on Novel Coronavirus Disease (COVID-19) prevention in cancer patients under treatment” in Iranian Registry of Clinical Trials (IRCT) with code “IRCT20200405046958N1”, https://www.irct.ir/trial/46946. Registration date is April 14, 2020. Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.